Invivyd

Yahoo Finance • 23 days ago

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02%

Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Financials, Technology and Telecoms sectors led shares higher. At the close in NYSE, the Dow Jones Industrial Average rose 0.02% to hit a new all time hig... Full story

Yahoo Finance • 11 months ago

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a... Full story

Yahoo Finance • last year

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will prese... Full story

Yahoo Finance • last year

Invivyd Appoints William Duke as Chief Financial Officer

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of... Full story

Yahoo Finance • last year

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Dentsply Sirona, Inc. (NASDAQ: XRAY), and Invivyd, Inc. (NASDAQ... Full story

Yahoo Finance • last year

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

Unique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated clinical trial data from prototype antibody VYD222 and potential future Invivyd... Full story

Yahoo Finance • last year

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to date As predicted by pre-clinical in vitro testing, early serum samples from the first, lowest dose cohort showed strong neutralizatio... Full story

Yahoo Finance • last year

Lifshitz Law PLLC Announces Investigations of Invivyd, Inc. (NASDAQ: IVVD), National Vision Holdings, Inc. (NASDAQ: EYE), Sunlight Financial Holdings Inc. (NYSE: SUNL), and Gaia, Inc. (NASDAQ: GAIA)

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Com... Full story

Yahoo Finance • last year

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a c... Full story

Yahoo Finance • last year

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial being conducted in Australia, with cohort 1 dosing completeDiscussions are underway with the FDA and global regulators regarding the company’s proposed VYD... Full story

Yahoo Finance • last year

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of... Full story

Yahoo Finance • last year

DEADLINE ALERT for ALIZY, IVVD, and RVYL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the... Full story

Yahoo Finance • last year

DEADLINE ALERT for IVVD, RVYL, TEAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • last year

Lifshitz Law PLLC Announces Investigations of Norfolk Southern Corporation (NYSE: NSC), Atlassian Corp. (NASDAQ: TEAM), Invivyd, Inc. (NASDAQ: IVVD), and National Vision Holdings, Inc. (NASDAQ: EYE)

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Norfolk Southern Corporation (NYSE: NSC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations... Full story

Yahoo Finance • last year

Holzer & Holzer, LLC Reminds Shareholders of Imminent Deadlines in Class Action Lawsuits Filed on Behalf of Invivyd, Inc. (IVVD), Ryvyl Inc. (RYVL), and Atlassian Corporation (TEAM) Investors and Encourages Investors With Significant Losses to Contact the Firm

ATLANTA, March 29, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors that class action lawsuits have been filed against Invivyd, Inc. (NASDAQ: IVVD), Ryvyl Inc. (NASDAQ: RYVL), and Atlassian Corporation (NASDAQ: TEAM). Inv... Full story

Yahoo Finance • last year

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RYVYL, Invivyd, Honda, and Allianz and Encourages Investors to Contact the Firm

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RYVYL Inc. (NASDAQ: RVYL... Full story

Yahoo Finance • last year

IVVD & ALIZY Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy o... Full story

Yahoo Finance • last year

Invivyd, Inc. (IVVD) Investor Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline in Invivyd, Inc. Class Action

SAN DIEGO, March 24, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Invivyd, Inc. (NASDAQ: IVVD) f/k/a Adagio Therapeutics, Inc. common stock betw... Full story

Yahoo Finance • last year

DEADLINE ALERT for IVVD, RVYL, SQ, TEAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • last year

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

Advancing VYD222 into clinical developmentbased on in vitro datademonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term designation of an additional monoclonal antibody ag... Full story